Forest Laboratories, Inc. announced today that NAMENDA XR(TM)
(memantine hydrochloride) once-daily formulation is now available in
pharmacies throughout the United States. NAMENDA XR is approved by the
U.S. Food and Drug Administration (FDA) for the treatment of moderate to
severe dementia of the Alzheimer's type.
New NAMENDA XR 28 mg is a higher dose, once-daily extended-release
formulation of NAMENDA (memantine) immediate-release. The efficacy and
safety of NAMENDA XR was established in a randomized, double-blind,
placebo-controlled trial of 677 outpatients on a stable dose of
acetylcholinesterase inhibitors (AChEl). AChEIs are a different class of
prescription drugs often used in combination with NAMENDA for the
treatment of moderate to severe Alzheimer's disease. The results of this
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in